Tonix Pharma Stock Moving Higher On Plans For Vaccine Manufacturing Facility In Bitterroot ValleyBenzinga • 06/25/21
Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC)GlobeNewsWire • 06/21/21
Tonix Pharmaceuticals to Present at Raymond James Human Health Innovation ConferenceGlobeNewsWire • 06/16/21
Tonix Pharma Fibromyalgia Treatment Associated with Improvement in Pain, Sleep, FatigueBenzinga • 06/03/21
Tonix Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational HighlightsGlobeNewsWire • 05/10/21
Tonix Pharma: Interesting Molecule In Fibromyalgia, But Generic Availability Is A ConcernSeeking Alpha • 05/02/21
Tonix Pharmaceuticals to Participate in Fourth Annual Neuroscience Innovation ForumGlobeNewsWire • 04/21/21
Tonix Pharma Stock Is Trading Higher On Expanding COVID-19 Candidate Portfolio With Sangivamycin Licensing PactBenzinga • 04/19/21
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive DisorderGlobeNewsWire • 03/22/21
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Compositions and Uses of Tianeptine Oxalate Salt, the Active Ingredient of TNX-601 CRGlobeNewsWire • 03/19/21